Targeting Tumor Cells with Antibodies and T-Cells
Author Information
Author(s): Ogg G S, Dunbar P R, Cerundolo V, McMichael A J, Lemoine N R, Savage P
Primary Institution: MRC Human Immunology Unit, Institute of Molecular Medicine, Oxford, OX3 9D5, UK
Hypothesis
Can antibody-targeted MHC class I/peptide complexes enhance the lysis of tumor cells by virus-specific cytotoxic T-lymphocytes?
Conclusion
The study demonstrates that linking MHC class I/peptide complexes to tumor cells can significantly enhance their lysis by specific cytotoxic T-cells.
Supporting Evidence
- Soluble recombinant MHC class I/peptide complexes were synthesized and confirmed for stability.
- Flow cytometry showed an 80-fold increase in labeling of lymphoma cells with HLA-A2/gag complexes.
- CTL specific for HLA-A2/gag efficiently lysed complex-targeted cells.
Takeaway
Researchers found a way to help immune cells better attack cancer cells by using special proteins that target the cancer cells.
Methodology
The study involved synthesizing MHC class I/peptide complexes and testing their ability to enhance lysis of tumor cells by cytotoxic T-cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website